Filing Details

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.  )*

 

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

☐  Rule 13d-1(b)

☒  Rule 13d-1(c)

☐  Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

* The beneficial ownership percentage is based upon 39,610,967 shares of common stock, $0.001 par value per share (“Common Stock”), of Anavex Life Sciences Corp., a Nevada corporation (the “Company”), issued and outstanding as of December 12, 2016, based on information reported by the Company in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission on December 14, 2016.  Park West Asset Management LLC (“PWAM”) is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”), and Park West Partners International, Limited, a Cayman Islands exempted company (“PWPI” and, collectively with PWIMF, the “PW Funds”), and Peter S. Park (“Mr. Park” and, collectively with PWAM and PWIMF, the “Reporting Persons”) is the sole member and manager of PWAM.  As of February 1, 2017, PWIMF held 1,875,118 shares of Common Stock and PWPI held 240,017 shares of Common Stock.  As a result of the foregoing, for purposes of Reg. Section 240.13d-3, PWAM and Mr. Park are each deemed to beneficially own 2,115,135 shares of Common Stock held in the aggregate by the PW Funds, or approximately 5.3% of the shares of Common Stock deemed to be issued and outstanding as of February 1, 2017.

 

The beneficial ownership percentage is based upon 39,610,967 shares of common stock, $0.001 par value per share (“Common Stock”), of Anavex Life Sciences Corp., a Nevada corporation (the “Company”), issued and outstanding as of December 12, 2016, based on information reported by the Company in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission on December 14, 2016.  Park West Asset Management LLC (“PWAM”) is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”), and Park West Partners International, Limited, a Cayman Islands exempted company (“PWPI” and, collectively with PWIMF, the “PW Funds”), and Peter S. Park (“Mr. Park” and, collectively with PWAM and PWIMF, the “Reporting Persons”) is the sole member and manager of PWAM.  As of February 1, 2017, PWIMF held 1,875,118 shares of Common Stock and PWPI held 240,017 shares of Common Stock.  As a result of the foregoing, for purposes of Reg. Section 240.13d-3, PWAM and Mr. Park are each deemed to beneficially own 2,115,135 shares of Common Stock held in the aggregate by the PW Funds, or approximately 5.3% of the shares of Common Stock deemed to be issued and outstanding as of February 1, 2017.

 

Item 1(a).

Name Of Issuer: Anavex Life Sciences Corp. (the “Company”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

This report on Schedule 13G (this “Schedule 13G”), is being jointly filed by (i) Park West Asset Management LLC (“PWAM”), a Delaware limited liability company and the investment manager to (a) Park West Investors Master Fund, Limited (“PWIMF”), a Cayman Islands exempted company that is the holder of 1,875,118 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company reported on this Schedule 13G, and (b) Park West Partners International, Limited (“PWPI” and, collectively with PWIMF, the “PW Funds”), a Cayman Islands exempted company that is the holder of 240,017 shares of Common Stock reported on this Schedule 13G and (ii) Peter S. Park, as the sole member and manager of PWAM (“Mr. Park” collectively with PWAM, the “Reporting Persons”).

The 2,115,135 shares of Common Stock held in the aggregate by the PW Funds, which constitute approximately 5.3% of the shares of Common Stock deemed to be outstanding as of February 1, 2017, may be deemed to be beneficially owned (x) indirectly by PWAM, as the investment adviser to PWIMF and PWPI, and (y) indirectly by Mr. Park, as the sole member and manager of PWAM.

  

* This Schedule 13G is being jointly filed by (i) PWAM, a Delaware limited liability company and the investment manager to (a) PWIMF, a Cayman Islands exempted company that is the holder of 1,875,118 shares of Common Stock of the Company reported on this Schedule 13G, and (b) PWPI, a Cayman Islands exempted company that is the holder of 240,017 shares of Common Stock of the Company reported on this Schedule 13G and (ii) Mr. Park, as the sole member and manager of PWAM.

The 2,115,135 shares of Common Stock held in the aggregate by the PW Funds, which constitute approximately 5.3% of the shares of Common Stock deemed to be outstanding as of February 1, 2017, may be deemed to be beneficially owned (x) indirectly by PWAM, as the investment adviser to PWIMF and PWPI, and (y) indirectly by Mr. Park, as the sole member and manager of PWAM.

 

 

 

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Anavex Life Sciences Corp., and further agree that this Joint Filing Agreement be included as Exhibit A to such Schedule 13G.  In evidence thereof, the undersigned hereby execute this agreement this 13th day of February, 2017.

  

 

 

 

	/s/	Peter S. Park
	Peter S. Park